Hepatic impairment
Information
- Disease name
- Hepatic impairment
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05582187 | Active, not recruiting | Phase 1 | A Clinical Trial of the Study Medicine (Called Fosmanogepix) in People With Hepatic Dysfunction. | October 31, 2022 | December 31, 2024 |
| NCT05009680 | Active, not recruiting | Phase 1/Phase 2 | A Single and Repeat Dose Trial in Participants With Hepatic Impairment | September 9, 2021 | July 4, 2023 |
| NCT04305392 | Active, not recruiting | Phase 1 | Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment | August 4, 2020 | December 2022 |
| NCT00672581 | Completed | Phase 1 | Pharmacokinetics, Safety & Tolerability of ZD4054 (Zibotentan) in Subjects With Normal, Mild, Moderate and Severe Hepatic Impairment | April 2008 | March 2009 |
| NCT00736905 | Completed | Phase 1 | TMC278-TiDP6-C130: Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function. | June 2008 | November 2009 |
| NCT00768209 | Completed | Phase 1 | A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment | October 2008 | July 2009 |
| NCT00791284 | Completed | Phase 1 | A Study of the Pharmacokinetics of Paliperidone in Volunteers With Normal or Impaired Liver Function | August 2004 | December 2004 |
| NCT00812305 | Completed | Phase 1 | Hepatic Impairment Study: Pharmacokinetics in Healthy and Hepatically Impaired Subjects | January 2009 | August 2009 |
| NCT00819468 | Completed | Phase 1 | Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared to Healthy Participants | July 26, 2007 | August 23, 2007 |
| NCT00828932 | Completed | Phase 1 | Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment | August 2008 | December 2008 |
| NCT00858156 | Completed | Phase 1 | BG9928 in Subjects With Hepatic Impairment | April 2009 | August 2009 |
| NCT00956306 | Completed | Phase 1 | A Pharmacokinetic Study of Udenafil in Adult Subjects With or Without Impaired Hepatic Function | November 2007 | September 2012 |
| NCT01027169 | Completed | Phase 1 | A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics | April 2009 | |
| NCT01126086 | Completed | Phase 1 | Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepatic Impairment | May 2010 | April 2011 |
| NCT01134185 | Completed | Phase 1 | Evaluation of Prucalopride in Subjects With Moderate and Severe Hepatic Impairment | May 2010 | February 2011 |
| NCT01146938 | Completed | Phase 1 | A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy Volunteers | May 2010 | February 2011 |
| NCT01222455 | Completed | Phase 1 | A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function | October 2010 | June 2011 |
| NCT01231529 | Completed | Phase 1 | GSK1349572 Hepatic Impairment Study | November 19, 2010 | June 4, 2011 |
| NCT01271387 | Completed | Phase 1 | Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment | January 2011 | August 2011 |
| NCT01319279 | Completed | Phase 1 | A Study to Evaluate the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Hepatic Function and Subjects With Moderate Hepatic Impairment | April 2011 | August 2011 |
| NCT01419457 | Completed | Phase 1 | Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment | August 2011 | February 2013 |
| NCT01429337 | Completed | Phase 1 | PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function | March 7, 2011 | May 9, 2020 |
| NCT01431833 | Completed | Phase 1 | A PK and Safety Study in Subjects With Hepatic Impairment | August 2011 | May 2012 |
| NCT01433458 | Completed | Phase 1 | Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Subjects | July 2011 | December 2011 |
| NCT01443481 | Completed | Phase 1 | Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function | November 2011 | October 2014 |
| NCT01456663 | Completed | Phase 1 | A Study to Evaluate the Pharmacokinetics of AFQ056 in Subjects With Hepatic Impairment Compared to Healthy Subjects | May 2011 | July 2012 |
| NCT01493869 | Completed | Phase 1 | Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects | September 2011 | August 2014 |
| NCT01516047 | Completed | Phase 1 | A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function | January 2012 | September 2012 |
| NCT01529294 | Completed | Phase 1 | Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers | August 2010 | July 2012 |
| NCT01531309 | Completed | Phase 1 | Pharmacokinetics of AGO178 in Participants With Liver Impairment | February 8, 2011 | September 2, 2011 |
| NCT01563562 | Completed | Phase 1 | Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function | April 30, 2012 | November 30, 2012 |
| NCT01565902 | Completed | Phase 1 | Pharmacokinetics of BAF312 in Patients With Hepatic Impairment | October 2012 | March 2014 |
| NCT01594957 | Completed | Phase 1 | Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment | April 2012 | April 2013 |
| NCT01600976 | Completed | Phase 1 | A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment | June 2012 | November 2012 |
| NCT01621633 | Completed | Phase 2 | A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers | September 2012 | January 2013 |
| NCT01631097 | Completed | Phase 1 | A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function | May 2012 | January 2014 |
| NCT01727128 | Completed | Phase 1 | Pharmacokinetic Study of BKM120 in Subjects With Hepatic Impairment | October 2011 | August 2013 |
| NCT01732263 | Completed | Phase 1 | Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function | November 9, 2012 | April 1, 2013 |
| NCT01762462 | Completed | Phase 1 | Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment | December 2012 | March 2013 |
| NCT01767103 | Completed | Phase 4 | An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers | January 2013 | April 2014 |
| NCT01767948 | Completed | Phase 1 | A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment | December 2012 | November 2013 |
| NCT01790607 | Completed | Phase 1 | An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment | February 2013 | |
| NCT01846455 | Completed | Phase 4 | Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects | September 2012 | May 2013 |
| NCT01863784 | Completed | Phase 1 | A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function | April 2013 | November 2013 |
| NCT01887301 | Completed | Phase 1 | Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients | July 2013 | May 2014 |
| NCT01888393 | Completed | Phase 1 | Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects | June 2013 | November 2013 |
| NCT01904539 | Completed | Phase 1 | Hepatic Impairment Trial of Obeticholic Acid | June 2013 | October 2013 |
| NCT01949545 | Completed | Phase 1 | Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment | October 2013 | September 2015 |
| NCT01984736 | Completed | Phase 1 | EVP-6124 Hepatic Impairment Study | June 2013 | |
| NCT02004587 | Completed | Phase 1 | Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White Volunteers | September 2013 | July 2014 |
| NCT02095587 | Completed | Phase 1 | Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects | March 2014 | October 2014 |
| NCT02115347 | Completed | Phase 1 | Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014) | September 19, 2014 | January 19, 2015 |
| NCT02121860 | Completed | Phase 1 | PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers | April 2014 | July 2014 |
| NCT02150733 | Completed | Phase 1 | Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment | April 2014 | July 2016 |
| NCT02242734 | Completed | Phase 1 | Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Controlled-Release (HC-CR) in Subjects With Hepatic Impairment | February 2011 | May 2011 |
| NCT00162097 | Completed | Phase 1 | Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment | November 2004 | March 2008 |
| NCT02245243 | Completed | Phase 1 | Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment | September 2014 | February 2015 |
| NCT02256033 | Completed | Phase 1 | Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline | August 2014 | December 2014 |
| NCT02286609 | Completed | Phase 1 | A Single Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort Pharmacokinetics | December 2014 | February 2015 |
| NCT02296905 | Completed | Phase 1 | Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function | October 2014 | September 2015 |
| NCT02367872 | Completed | Phase 1 | Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment | March 2015 | June 2016 |
| NCT02372084 | Completed | Phase 1 | A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function | April 21, 2015 | May 19, 2016 |
| NCT02421042 | Completed | Phase 1 | A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg) | June 2011 | July 2012 |
| NCT02452801 | Completed | Phase 1 | Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function | May 2015 | December 2015 |
| NCT02471274 | Completed | Phase 1 | PK Study of Sotagliflozin in Subjects With Hepatic Impairment | June 2015 | |
| NCT02474537 | Completed | Phase 1 | INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function | June 12, 2015 | September 12, 2017 |
| NCT02524717 | Completed | Phase 1 | A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function | August 13, 2015 | February 9, 2017 |
| NCT02571816 | Completed | Phase 1 | A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215 | October 23, 2015 | March 5, 2016 |
| NCT02581592 | Completed | Phase 1 | Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment | November 2015 | April 2016 |
| NCT02611505 | Completed | Phase 1 | A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine | November 30, 2015 | February 27, 2017 |
| NCT02621047 | Completed | Phase 1 | Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib | December 4, 2015 | December 8, 2016 |
| NCT02624557 | Completed | Phase 1 | Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment. | December 21, 2015 | October 1, 2017 |
| NCT02683577 | Completed | Phase 1 | Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects | February 2016 | July 2016 |
| NCT02693197 | Completed | Phase 1 | PK Study of T-817 in Subjects With Hepatic Impairment | February 2016 | August 2016 |
| NCT02857868 | Completed | Phase 1 | A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects | May 3, 2016 | July 20, 2017 |
| NCT02244827 | Completed | Phase 1 | Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment | September 2014 | June 2015 |
| NCT00432627 | Completed | Phase 1 | Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox. | December 2006 | August 2010 |
| NCT00621725 | Completed | Phase 1 | Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours | January 2008 | January 2014 |
| NCT04293029 | Completed | Phase 1 | Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic Impairment | May 20, 2020 | December 30, 2020 |
| NCT04332432 | Completed | Phase 1 | A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment | June 16, 2020 | March 9, 2022 |
| NCT04406896 | Completed | Phase 1 | The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics | July 22, 2020 | October 23, 2020 |
| NCT04473664 | Completed | Phase 1 | A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment | September 22, 2020 | July 22, 2021 |
| NCT04482270 | Completed | Phase 1 | A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function | September 2, 2020 | March 22, 2021 |
| NCT04546789 | Completed | Phase 1 | Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK | September 30, 2020 | May 16, 2021 |
| NCT04552808 | Completed | Phase 1 | To Evaluate the Pharmacokinetics and Safety of Yimitasvir Phosphate Capsules in Subjects With Moderate and Severe Liver Function Impairment and in Healthy Subjects | October 19, 2020 | June 9, 2022 |
| NCT04573582 | Completed | Phase 1 | Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment | November 13, 2020 | March 8, 2023 |
| NCT04604496 | Completed | Phase 1 | STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT | December 30, 2020 | January 10, 2022 |
| NCT04643795 | Completed | Phase 1 | Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects | October 25, 2018 | August 4, 2021 |
| NCT04676425 | Completed | Phase 1 | A Study to Investigate the Influence of Hepatic Impairment on MK-8189 Treatment (MK-8189-012) | March 17, 2021 | January 25, 2022 |
| NCT04752540 | Completed | Phase 1 | A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment | July 2, 2021 | October 24, 2021 |
| NCT04755075 | Completed | Phase 1 | Surufatinib Hepatic Impairment Study | February 12, 2021 | October 11, 2021 |
| NCT04772612 | Completed | Phase 1 | A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib | March 12, 2021 | April 13, 2023 |
| NCT04791553 | Completed | Phase 1 | Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment | June 17, 2021 | August 11, 2023 |
| NCT04859426 | Completed | Phase 1 | A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Hepatic Impairment | June 9, 2021 | May 17, 2022 |
| NCT04887064 | Completed | Phase 1 | Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment | April 22, 2021 | March 9, 2022 |
| NCT04942964 | Completed | Phase 1 | A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function | September 13, 2021 | January 20, 2022 |
| NCT04960124 | Completed | Phase 1 | A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants | August 5, 2021 | November 19, 2021 |
| NCT04993157 | Completed | Phase 1 | Pharmacokinetics Study of FIA586 in Participants With Mild and Moderate Hepatic Impairment | December 10, 2021 | June 28, 2022 |
| NCT05005312 | Completed | Phase 1 | Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332 | August 31, 2021 | December 7, 2021 |
| NCT05026996 | Completed | Phase 1 | Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants | November 23, 2021 | October 19, 2022 |
| NCT05078580 | Completed | Phase 1 | Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function. | November 10, 2021 | June 20, 2022 |
| NCT05098054 | Completed | Phase 1 | A Study of Soticlestat in Adults With Liver Failure Compared to Those With Normal Liver Function | October 29, 2021 | June 7, 2022 |
| NCT05112419 | Completed | Phase 1 | A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal Impairment | November 10, 2021 | December 15, 2021 |
| NCT05112952 | Completed | Phase 1 | A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937) | November 30, 2021 | July 11, 2022 |
| NCT05216367 | Completed | Phase 1 | Fruquintinib Hepatic Impairment Study | March 11, 2022 | October 25, 2022 |
| NCT05386589 | Completed | Phase 1 | A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016) | June 14, 2022 | January 5, 2023 |
| NCT05391724 | Completed | Phase 1 | Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects | February 2011 | September 2011 |
| NCT05404529 | Completed | Phase 1 | To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function | April 29, 2022 | January 24, 2023 |
| NCT05409911 | Completed | Phase 1 | A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants | September 13, 2022 | April 25, 2023 |
| NCT05419635 | Completed | Phase 1 | A Study to Learn How the Study Treatment Asundexian Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body in Participants With Mild or Moderate Reduction of Liver Function Compared to Participants With Normal Liver Function | June 14, 2022 | August 21, 2023 |
| NCT05436912 | Completed | Phase 1 | A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants | December 10, 2018 | October 30, 2019 |
| NCT05467722 | Completed | Phase 1 | Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543 | June 1, 2022 | September 21, 2022 |
| NCT05478603 | Completed | Phase 1 | A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction | August 1, 2022 | April 5, 2023 |
| NCT05481411 | Completed | Phase 1 | A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment | September 13, 2022 | May 31, 2023 |
| NCT05515445 | Completed | Phase 1 | Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function | December 3, 2022 | August 23, 2023 |
| NCT05517525 | Completed | Phase 1 | A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | October 4, 2022 | June 1, 2023 |
| NCT05599932 | Completed | Phase 1 | Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment | December 2, 2022 | September 18, 2023 |
| NCT05674474 | Completed | Phase 1 | A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function | March 14, 2023 | July 18, 2023 |
| NCT05706623 | Completed | Phase 1 | A Phase 1, Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function | January 30, 2023 | April 4, 2023 |
| NCT05707390 | Completed | Phase 1 | A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment | February 20, 2023 | September 13, 2023 |
| NCT05753592 | Completed | Phase 1 | A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants | October 31, 2022 | December 17, 2023 |
| NCT05790304 | Completed | Phase 1 | Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects | February 20, 2023 | February 22, 2024 |
| NCT05814926 | Completed | Phase 1 | GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers | April 26, 2023 | October 20, 2023 |
| NCT05835180 | Completed | Phase 1 | A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function | May 1, 2023 | December 18, 2023 |
| NCT05856513 | Completed | Phase 1 | Pharmacokinetics of ZSP1273 in Participants With Hepatic Impairment | June 15, 2023 | July 4, 2023 |
| NCT05857644 | Completed | Phase 1 | A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants. | June 7, 2023 | February 7, 2024 |
| NCT06004934 | Completed | Phase 1 | A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic Impairment | April 17, 2018 | September 18, 2018 |
| NCT06094725 | Completed | Phase 1 | A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant | January 6, 2020 | December 14, 2020 |
| NCT06161259 | Completed | Phase 1 | Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Hepatic Impairment | September 14, 2023 | October 7, 2023 |
| NCT03048448 | Completed | Phase 1 | Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects | May 31, 2017 | April 22, 2019 |
| NCT03114540 | Completed | Phase 1 | Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment | March 17, 2017 | March 22, 2018 |
| NCT03189615 | Completed | Phase 1 | Study Investigating the Pharmacokinetic Properties of the Drug Lu AF35700 in Subjects With Liver Impairment and in Healthy Subjects | May 14, 2017 | April 23, 2018 |
| NCT03277274 | Completed | Phase 1 | A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954 | November 9, 2017 | September 10, 2018 |
| NCT03282513 | Completed | Phase 1 | A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function | September 26, 2017 | March 31, 2018 |
| NCT03289234 | Completed | Phase 1 | Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment | November 16, 2016 | July 24, 2018 |
| NCT03290443 | Completed | Phase 1 | A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment. | September 21, 2017 | October 26, 2018 |
| NCT03309202 | Completed | Phase 1 | Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment | December 19, 2017 | July 18, 2018 |
| NCT03359850 | Completed | Phase 1 | Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients | February 20, 2018 | June 24, 2020 |
| NCT03369002 | Completed | Phase 1 | Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects | November 27, 2017 | May 15, 2018 |
| NCT03376841 | Completed | Phase 1 | Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites | June 6, 2017 | December 17, 2017 |
| NCT03397888 | Completed | Phase 1 | The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist | November 16, 2017 | January 16, 2018 |
| NCT03423446 | Completed | Phase 1 | Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment | November 28, 2017 | June 15, 2018 |
| NCT03440424 | Completed | Phase 1 | Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects | January 26, 2018 | April 23, 2018 |
| NCT03534843 | Completed | A Comparison Between Child-Pugh and Albumin-Bilirubin Scores | January 1, 2005 | January 1, 2018 | |
| NCT03546608 | Completed | Phase 1 | Tepotinib Hepatic Impairment Trial | June 13, 2018 | February 5, 2019 |
| NCT03555539 | Completed | Phase 1 | Study of Danicopan in Participants With Hepatic Impairment | May 1, 2018 | September 21, 2018 |
| NCT03626415 | Completed | Phase 1 | A Hepatic Impairment Study for PF-04965842. | October 1, 2018 | April 30, 2019 |
| NCT03627754 | Completed | Phase 1 | A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib | November 5, 2018 | April 11, 2019 |
| NCT03706898 | Completed | Phase 1 | Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs | October 1, 2018 | April 10, 2019 |
| NCT03713242 | Completed | Phase 1 | A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment | February 26, 2018 | February 27, 2020 |
| NCT03722823 | Completed | Phase 1 | A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects | October 10, 2018 | May 7, 2019 |
| NCT03742882 | Completed | Phase 1 | A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects | December 6, 2018 | June 10, 2019 |
| NCT03765671 | Completed | Phase 1 | Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients | December 12, 2018 | June 14, 2019 |
| NCT03799848 | Completed | Phase 1 | A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function | June 12, 2018 | October 18, 2018 |
| NCT03802786 | Completed | Phase 1 | Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects | November 6, 2018 | July 8, 2019 |
| NCT03816631 | Completed | Phase 1 | A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment | May 28, 2019 | April 27, 2020 |
| NCT03824678 | Completed | Phase 1 | Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects | February 13, 2019 | June 18, 2019 |
| NCT03832426 | Completed | Phase 1 | A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched Volunteers | November 8, 2013 | October 24, 2014 |
| NCT03902002 | Completed | Phase 1 | A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function | July 19, 2019 | January 27, 2020 |
| NCT03962049 | Completed | Phase 1 | Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function | May 15, 2019 | November 1, 2019 |
| NCT03968848 | Completed | Phase 1 | Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite | November 12, 2018 | March 29, 2019 |
| NCT03983161 | Completed | Phase 1 | A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment | September 4, 2019 | January 5, 2023 |
| NCT04016077 | Completed | Phase 1 | A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers | July 19, 2019 | March 5, 2020 |
| NCT04056468 | Completed | Phase 1 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function | October 9, 2020 | February 26, 2022 |
| NCT04091061 | Completed | Phase 1 | Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects | October 3, 2019 | April 7, 2020 |
| NCT04145596 | Completed | Phase 1 | Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Hepatic Impairment | November 14, 2019 | July 13, 2020 |
| NCT04166942 | Completed | Phase 1 | KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment | December 11, 2019 | June 6, 2022 |
| NCT04190654 | Completed | Phase 1 | Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite | November 26, 2019 | March 20, 2020 |
| NCT04193436 | Completed | Phase 1 | A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT | January 21, 2020 | July 9, 2021 |
| NCT04208165 | Completed | N/A | PVB Versus TAP in Hepatic Patients Undergoing Laparoscopic Cholecystectomy | December 29, 2019 | June 25, 2020 |
| NCT04208386 | Completed | Phase 1 | A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989 | January 8, 2020 | July 20, 2020 |
| NCT04208399 | Completed | Phase 1 | A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379 | January 9, 2020 | March 26, 2021 |
| NCT04225936 | Completed | Phase 1 | A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment | January 16, 2020 | June 1, 2021 |
| NCT04252495 | Completed | Phase 1 | The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics | June 26, 2020 | May 6, 2021 |
| NCT04271098 | Completed | The Investigation of the Causes of Hepatic Dysfunction in the Postoperative Period During Open-heart Surgeries | January 1, 2012 | September 1, 2012 | |
| NCT04276662 | Completed | Phase 1 | Study of Single-dose DS-3201b in Participants With Hepatic Impairment | November 21, 2019 | February 23, 2021 |
| NCT06425198 | Not yet recruiting | Phase 1 | Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment | June 10, 2024 | December 23, 2024 |
| NCT05731804 | Not yet recruiting | Phase 1 | Hepatic Impairment and Renal Impairment Study of SIM0417 Combined With Ritonavir | March 1, 2023 | December 31, 2023 |
| NCT03606538 | Not yet recruiting | Phase 1 | MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function | March 29, 2026 | December 2028 |
| NCT05684653 | Recruiting | Phase 1 | Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject | March 17, 2023 | December 30, 2023 |
| NCT04241835 | Recruiting | Phase 1 | A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function | January 28, 2020 | June 28, 2025 |
| NCT06048302 | Recruiting | Phase 1 | PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function | November 30, 2023 | July 30, 2024 |
| NCT05101265 | Recruiting | Phase 1 | Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment | March 9, 2021 | June 1, 2025 |
| NCT04271488 | Recruiting | Phase 1 | Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants | February 27, 2020 | November 30, 2024 |
| NCT06052566 | Recruiting | Phase 1 | A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014) | November 21, 2023 | August 26, 2024 |
| NCT05724693 | Recruiting | Phase 1 | Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function | January 30, 2023 | March 29, 2024 |
| NCT06388616 | Recruiting | Phase 1 | Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone | May 2, 2024 | November 15, 2024 |
| NCT05045482 | Recruiting | Phase 1 | Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease | October 21, 2021 | July 2024 |
| NCT04469920 | Recruiting | Phase 1 | Hepatic Impairment, Cholestatic Liver Disease, & NASH With Advanced Fibrosis & Normal Hepatic Function | July 16, 2020 | October 2024 |
| NCT05751759 | Recruiting | Phase 1 | Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment | March 20, 2023 | August 20, 2024 |
| NCT06084104 | Recruiting | Phase 1 | DZD9008 PK Study in Hepatic Impairment Subjects | October 17, 2023 | May 2024 |
| NCT06402721 | Recruiting | Phase 1 | A Study to Learn About How BAY 3283142 Moves Into, Through, and Out of the Body After a Single Dose in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function | May 17, 2024 | January 10, 2025 |
| NCT06126575 | Recruiting | Phase 1 | A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function | March 13, 2023 | December 30, 2024 |
| NCT06179368 | Recruiting | Throid Dysfunction in Liver Failure and Its Eddects Upon Outcome | January 1, 2024 | May 1, 2024 | |
| NCT04631549 | Recruiting | Phase 1 | An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy Participants | February 3, 2021 | July 2023 |
| NCT06352528 | Recruiting | Phase 1 | A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment | April 29, 2024 | July 24, 2025 |
| NCT05891158 | Recruiting | Phase 1 | A Study About Fazirsiran in People With and Without Liver Problems | October 5, 2023 | April 15, 2025 |
| NCT05917938 | Recruiting | Phase 1 | A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function | July 5, 2023 | August 17, 2024 |
| NCT05484206 | Recruiting | Phase 1 | Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 | September 21, 2022 | April 30, 2027 |
| NCT05919069 | Recruiting | Phase 1 | A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693 | June 16, 2023 | September 9, 2024 |
| NCT04819464 | Recruiting | Phase 1 | A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod | August 19, 2021 | March 29, 2024 |
| NCT05935033 | Recruiting | Phase 1 | A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine | June 30, 2023 | December 23, 2024 |
| NCT05552183 | Recruiting | Phase 1 | Study to Evaluate the Safety, Tolerability, and PK of Pacritinib | December 12, 2022 | May 2024 |
| NCT04950764 | Recruiting | Phase 1 | An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI) | September 17, 2021 | June 2024 |
| NCT04154774 | Recruiting | Phase 1 | A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function | November 7, 2019 | September 24, 2024 |
| NCT05564104 | Recruiting | Phase 1 | A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Behaves in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function | April 5, 2023 | January 3, 2025 |
| NCT05976321 | Recruiting | Phase 1 | A Study of TAK-279 in Adults With or Without Liver Damage | September 22, 2023 | August 8, 2024 |
| NCT03212313 | Terminated | Phase 1 | Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant | June 30, 2017 | December 31, 2017 |
| NCT03587363 | Terminated | Phase 1 | A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib | December 6, 2018 | December 22, 2020 |
| NCT02873650 | Terminated | Phase 1 | Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment | December 20, 2016 | April 8, 2019 |
| NCT05517226 | Terminated | Phase 1 | Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment | September 6, 2022 | February 27, 2023 |
| NCT04332523 | Terminated | Phase 1 | A Study of JNJ-53718678 in Participants With Hepatic Impairment | August 17, 2020 | March 16, 2022 |
| NCT05376839 | Terminated | Phase 1 | A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic Impairment | July 6, 2022 | November 8, 2022 |
| NCT02050815 | Terminated | Phase 1 | MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function | March 2014 | August 26, 2016 |
| NCT04631575 | Unknown status | Phase 1 | An Investigational Study of SHR6390 in Participants With Mild to Moderate Liver Impairment and Healthy Participants | December 2020 | March 2021 |
| NCT02893657 | Unknown status | The Role and Dynamics of Liver Dysfunction in Patients Undergoing Cardiac Surgery | December 1, 2017 | May 2023 | |
| NCT04480827 | Unknown status | Phase 1 | Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment | January 22, 2020 | July 2021 |
| NCT04694365 | Unknown status | Phase 1 | Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Liver Function | November 6, 2020 | July 2021 |
| NCT04494269 | Unknown status | Phase 1 | A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls | September 8, 2020 | December 2023 |
| NCT04020016 | Unknown status | Phase 1 | Nalbuphine ER Effects of Liver Disease on Pharmacokinetics and Itch | October 24, 2018 | December 2020 |
| NCT03160014 | Unknown status | Phase 1 | Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Patients With Hepatic Impairment | June 2015 | December 2017 |
| NCT03277755 | Withdrawn | Phase 1 | A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic Function | September 11, 2017 | December 22, 2017 |
| NCT05490030 | Withdrawn | Phase 1 | Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants | March 6, 2025 | June 26, 2025 |
| NCT02985632 | Withdrawn | Phase 1 | A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants | January 11, 2017 | July 7, 2017 |
| NCT03813979 | Withdrawn | Phase 4 | Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls. | November 15, 2020 | December 31, 2021 |
| NCT03499041 | Withdrawn | Phase 1 | A Study of LY3314814 in Participants With Liver Impairment | June 2018 | December 2018 |
| NCT04759846 | Withdrawn | Phase 1 | Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma | January 21, 2021 | May 2023 |